Search results for ''
Vonafexor series
ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function like Alport syndrome, CKD and NASH.
Vonafexor (EYP001)
Vonafexor is a synthetic non-steroidal, non-bile acid NR1H4* agonist. It activates FXR with a high selectivity compared to other nuclear receptors and does not display any activity on bile acid receptor TGR5.
This small molecule has a different structure compared to other FXR agonists and induces a differential set of target genes based on ligand binding patterns.
5th CKD Summit – Chronic Kidney Disease Drug Development
7-9 March, 2023
Boston, MA
ENYO was attending the 5th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
ENYO Pharma is proud to share the publication of the results from our Phase 2 LIVIFY study with Vonafexor in NASH patients in Journal of Hepatology.
This article describes the remarkable effects of Vonafexor after only 12 weeks of treatment in these patients: strong liver fat reduction, weight loss, liver enzyme improvements …., and last but not least renal function recovery. These strongly differentiated fibrolytic and anti-inflammatory effects of Vonafexor compared to other FXR agonists correlate very well with those observed in several preclinical models of severe CKD and rare kidney diseases like Alport Syndrome.
2022 International HBV Meeting
18-22 September, 2022
Paris, France.
ENYO Pharma sponsored and attent the 2022 International HBV Meeting on 18-22 September, 2022 organized by our collaborator Dr. David Durantel, Director of Research in Infectiology and team leader at the International Center for Research in Infectiology (CIRI-INSERM), Lyon, France.
https://www.hbvmeeting.org/
Latest Press Release 